Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

M.E. O'Dwyer; R. Swords; F. Giles; Mary Frances McMullin; P.D. Le Coutre; A. Nagler; S. Langabeer; M. Wieczorkowska; C. McDowell; K. Egan; B. Moulton; E. Conneally

Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

M.E. O'Dwyer, R. Swords, F. Giles, Mary Frances McMullin, P.D. Le Coutre, A. Nagler, S. Langabeer, M. Wieczorkowska, C. McDowell, K. Egan, B. Moulton, E. Conneally

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1612-1613
Number of pages	2
Journal	Blood
Volume	118
Publication status	Published - Dec 2011

Cite this

O'Dwyer, M. E., Swords, R., Giles, F., McMullin, M. F., Le Coutre, P. D., Nagler, A., Langabeer, S., Wieczorkowska, M., McDowell, C., Egan, K., Moulton, B., & Conneally, E. (2011). Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). Blood, 118, 1612-1613.

O'Dwyer, M.E. ; Swords, R. ; Giles, F. ; McMullin, Mary Frances ; Le Coutre, P.D. ; Nagler, A. ; Langabeer, S. ; Wieczorkowska, M. ; McDowell, C. ; Egan, K. ; Moulton, B. ; Conneally, E. / Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). In: Blood. 2011 ; Vol. 118. pp. 1612-1613.

@article{b2acf3ee2e2445c0a437b37c0b8843b5,

title = "Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)",

author = "M.E. O'Dwyer and R. Swords and F. Giles and McMullin, {Mary Frances} and {Le Coutre}, P.D. and A. Nagler and S. Langabeer and M. Wieczorkowska and C. McDowell and K. Egan and B. Moulton and E. Conneally",

year = "2011",

month = dec,

language = "English",

volume = "118",

pages = "1612--1613",

journal = "Blood",

issn = "0006-4971",

publisher = "AMER SOC HEMATOLOGY",

}

O'Dwyer, ME, Swords, R, Giles, F, McMullin, MF, Le Coutre, PD, Nagler, A, Langabeer, S, Wieczorkowska, M, McDowell, C, Egan, K, Moulton, B & Conneally, E 2011, 'Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)', Blood, vol. 118, pp. 1612-1613.

Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). / O'Dwyer, M.E.; Swords, R.; Giles, F.; McMullin, Mary Frances; Le Coutre, P.D.; Nagler, A.; Langabeer, S.; Wieczorkowska, M.; McDowell, C.; Egan, K.; Moulton, B.; Conneally, E.

In: Blood, Vol. 118, 12.2011, p. 1612-1613.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

AU - O'Dwyer, M.E.

AU - Swords, R.

AU - Giles, F.

AU - McMullin, Mary Frances

AU - Le Coutre, P.D.

AU - Nagler, A.

AU - Langabeer, S.

AU - Wieczorkowska, M.

AU - McDowell, C.

AU - Egan, K.

AU - Moulton, B.

AU - Conneally, E.

PY - 2011/12

Y1 - 2011/12

M3 - Article

VL - 118

SP - 1612

EP - 1613

JO - Blood

JF - Blood

SN - 0006-4971

ER -